Clinical Trial Update: A Ph1b/2 Study of Axatilimab Monotherapy in Chinese Participants With Recurrent or Refractory cGVHD [Phase 1, Phase 2]

View source ↗

Summary

An update on a Phase 1b/2 trial of axatilimab as monotherapy in Chinese participants with recurrent or refractory chronic graft-versus-host-disease (cGVHD) that…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Axatilimab (axatilimab)

Snippet

Sponsor: Incyte Corporation | Conditions: Chronic Graft-versus-host-disease | Phase 1, Phase 2 | Status: RECRUITING